trending Market Intelligence /marketintelligence/en/news-insights/trending/75q3cikf25kuiz3yp8kjiw2 content esgSubNav
In This List

Intec Pharma appoints director

Blog

Insight Weekly: Private equity slows; SPAC underwriters retreat; carbon capture boost

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms


Intec Pharma appoints director

Intec Pharma Ltd. appointed Roger Pomerantz as a director.

Pomerantz's appointment brings the number of Intec's board members to seven, six of whom are independent. Pomerantz is the president, CEO and board chairman of Seres Therapeutics Inc.

Jerusalem, Israel-based Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Accordion Pill is an oral drug delivery system designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.